Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

2023206 citationsJournal Articlehybrid Open Access

Authors

Stephen J. Nicholls · Monash University

Deepak L. Bhatt · Mount Sinai Health System

John B. Buse · University of North Carolina at Chapel Hill

Stefano Del Prato · Scuola Superiore Sant'Anna

Steven E. Kahn · VA Puget Sound Health Care System

A. Michael Lincoff · Cleveland Clinic

Darren K. McGuire

Abstract

SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Diet and metabolism studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Heart Journal

Volume 267, pp. 1-11

DOI: 10.1016/j.ahj.2023.09.007

Field-Weighted Citation Impact: 40.97